Company Description
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.
The company’s drug candidates include AVTX-009, an Anti-IL-1β monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases.
The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021.
Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2011 |
| IPO Date | Oct 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Garry Neil |
Contact Details
Address: 540 Gaither Road, Suite 400 Rockville, Maryland 20850 United States | |
| Phone | 410-522-8707 |
| Website | avalotx.com |
Stock Details
| Ticker Symbol | AVTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534120 |
| CUSIP Number | 05338F108 |
| ISIN Number | US05338F3064 |
| Employer ID | 45-0705648 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Garry A. Neil M.D. | Chairman of the Board, President and Chief Executive Officer |
| Christopher Ryan Sullivan | Chief Financial Officer and Head of Investor relations |
| Dr. Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board |
| Dr. Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board |
| Paul C. Varki J.D., M.P.H | Chief Legal Officer |
| Dr. Lisa Hegg Ph.D. | Senior Vice President of Program Management, Corporate Infrastructure and Clinical Operations |
| Colleen Matkowski | Senior Vice President of Global Regulatory Affairs and Quality Assurance |
| Dr. Dino C. Miano Ph.D. | Senior Vice President of CMC and Technical Operations |
| Dr. Mittie Doyle FACR, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 8, 2024 | 8-K | Current Report |
| Oct 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 9, 2024 | 8-K | Current Report |
| Sep 4, 2024 | 8-K | Current Report |
| Aug 23, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 23, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 23, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |